Figure 3.
Cumulative incidence of relapse and overall mortality in the combined COG randomized trials of DRZ. Cumulative incidences at 10 years were not significantly different by DRZ status for either outcome. DRZ, dexrazoxane; DRZ+, exposed to DRZ; DRZ−, not exposed to DRZ. Adapted with permission from Chow et al.17